Literature DB >> 32320041

Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

Alfredo Piccerillo1,2, Maya El Hachem3, Rita De Vito4, Erika Valentina De Luca1,2, Ketty Peris1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32320041     DOI： 10.1001/jamadermatol.2020.0304

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  4 in total

Review 1.  Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.

Authors:  Domenico Bonamonte; Angela Filoni; Aurora De Marco; Lucia Lospalluti; Eleonora Nacchiero; Valentina Ronghi; Anna Colagrande; Giuseppe Giudice; Gerardo Cazzato
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

Review 2.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

3.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

4.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.